Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
Main Authors: | Matteo Fassan, Fotios Loupakis, Sara Lonardi, Federica Morano, Mariaelena Casagrande, Filippo Pietrantonio, Gianluca Masi, Marco Messina, Andrea Sartore-Bianchi, Paola Del Bianco, Francesca Bergamo, Angela Buonadonna, Vittorina Zagonel, Massimiliano Spada, Monica Ronzoni, Salvatore Corallo, Michele Prisciandaro, Giovanni Luca Frassineti, Alessandra Anna Prete, Vincenzo Formica, Domenico Cristiano Corsi, Corrado Orciuolo, Maria Giulia Zampino, Mario Scartozzi, Stefania Mosconi, Margherita Ratti, Emiliano Tamburini, Valentina Vettore |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/11/e002996.full |
Similar Items
-
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
by: Fotios Loupakis, et al.
Published: (2019-11-01) -
An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
by: Alessandra Anna Prete, et al.
Published: (2022-01-01) -
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
by: Zoran Andric, MD, et al.
Published: (2023-02-01) -
Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
by: Joseph Tintelnot, et al.
Published: (2022-12-01) -
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)